Back to top
more

C4 Therapeutics (CCCC)

(Delayed Data from NSDQ)

$6.06 USD

6.06
842,519

+0.02 (0.33%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $6.04 -0.02 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 12.50% and 158.10%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 29.73% and 74.51%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Community Health Systems (CYH) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Community Health Systems (CYH) delivered earnings and revenue surprises of -54.55% and 1.96%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?

by Zacks Equity Research

C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why

by Zacks Equity Research

C4 Therapeutics (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -1.49% and 37.59%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline

by Zacks Equity Research

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

When C4 Therapeutics, Inc. (CCCC), a clinical-stage biopharmaceutical company, reports fourth-quarter results, the focus will primarily be on pipeline progress.

C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Inhibrx, Inc. (INBX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn

by Zacks Equity Research

The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.

C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

Axsome (AXSM) Surges 7.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

Axsome (AXSM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why

by Zacks Equity Research

C4 Therapeutics (CCCC) shares surge on a licensing deal to develop degrader-antibody conjugates with Merck and positive data from CFT7455 studies.

Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 197.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?

by Zacks Equity Research

Here is how Aquestive Therapeutics (AQST) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.

The Zacks Analyst Blog Highlights Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics

by Zacks Equity Research

Allogene Therapeutics, Arcutis Biotherapeutics and C4 Therapeutics are part of the Zacks top Analyst Blog.

Sundeep Ganoria headshot

3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying

by Sundeep Ganoria

We present three small biotech stocks, which most analysts on Wall Street are optimistic about. These companies have upside potential for 2024 following signals of a stabilizing market.

Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for C4 Therapeutics, Inc. (CCCC) points to a 223% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck

by Zacks Equity Research

C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.

Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 1.35% and 69.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of 8.97% and 43.96%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Down -29.73% in 4 Weeks, Here's Why You Should You Buy the Dip in C4 Therapeutics, Inc. (CCCC)

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

C4 Therapeutics, Inc. (CCCC) delivered earnings and revenue surprises of -5.56% and 66.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?